Related Experiment Video
Updated: Aug 4, 2026
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
A comparative study on serum lipoprotein (a) and lipid profile between rheumatoid arthritis patients and normal
K P Shiva Govindan1, Saleem Basha1, V Ramesh2
1Department of Biochemistry, Melmaruvathur Adhiparasakthi Institute of Medical Science and Research, Melmaruvathur, Tamil Nadu, India.
Insights
Patients with rheumatoid arthritis have elevated Lipoprotein (a) [Lp (a)], a marker linked to increased cardiovascular disease risk. Monitoring Lp (a) alongside standard lipid profiles aids in assessing and managing this risk.
Area of Science:
- Cardiology
- Rheumatology
- Clinical Biochemistry
Background:
- Rheumatoid arthritis (RA) is a systemic inflammatory condition associated with increased atherosclerosis risk.
- Lipoprotein (a) [Lp (a)] is implicated in plaque formation and cardiovascular disease (CVD) development.
- RA patients frequently experience comorbidities like coronary artery disease.
Purpose of the Study:
- To assess Lipoprotein (a) [Lp (a)] as a cardiovascular risk factor in rheumatoid arthritis patients.
- To compare Lp (a) and lipid profiles between RA patients and healthy controls.
Main Methods:
- A comparative study involving 30 RA patients and 30 age/sex-matched healthy controls.
- Serum Lp (a) and lipid profiles (total cholesterol, triglycerides, HDL-C, VLDL-C) were analyzed.
- Statistical analysis was conducted using SPSS version 17.
Main Results:
- Significantly higher serum Lp (a) levels were observed in RA patients compared to controls (P < 0.001).
- RA patients showed significantly lower high-density lipoprotein-cholesterol (HDL-C) levels (P < 0.05).
- No significant differences were found in total cholesterol, triglycerides, or very low-density lipoprotein-cholesterol (VLDL-C) between groups.
Conclusions:
- Elevated Lp (a) levels in RA patients indicate a heightened future risk of cardiovascular disease.
- Lp (a) estimation, in addition to conventional lipid profiles, is valuable for cardiovascular risk assessment in RA.
- Monitoring Lp (a) can aid in the management of rheumatoid arthritis and associated cardiovascular risks.
Background:
Rheumatoid arthritis is a chronic and systemic inflammatory disorder, in which Lipoprotein (a) [Lp (a)] increases plaque formation and thus promotes atherosclerosis. Coronary artery disease is one of the co-morbidity in rheumatoid arthritis patients.
Aim:
The aim of this study is to evaluate Lp (a) as a cardiovascular risk factor in patients with rheumatoid arthritis. This was a comparative study in which Lp (a) and lipid profile were compared in rheumatoid arthritis patients and controls.
Materials And Methods:
The study included 30 sero-positive rheumatoid arthritis patients and 30 normal healthy subjects with an age and sex matched group of 25-80 years. Statistical analysis was performed using SPSS version 17.
Results:
Serum Lp (a) concentration was significantly increased (P < 0.001) in rheumatoid arthritis patients compared with controls. Serum high-density lipoprotein-cholesterol was significantly lowered (P < 0.05) in patients as compared to controls. There was no significant difference in serum total cholesterol, triglycerides, and very low density lipoprotein-cholesterol between patients and controls.
Conclusion:
The findings indicate that the patients with rheumatoid arthritis are at high risk of developing cardiovascular disease in future due to the increased level of Lp (a). In addition to conventional lipid profile, estimation of Lp (a) can prove to be a valuable tool in risk assessment of population in general and management of disease in particular.
More Related Videos
07:44Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
Published on: July 14, 2023
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
